Organization
FTC Targets Pharmacy Benefit Managers Over Exorbitant Price Hikes on Specialty Generic Drugs
FTC, Pharmacy Benefit Managers, PBM, Specialty Generic Drugs, Price Hikes, Healthcare Costs
Gilead and LEO Pharma Collaborate on STAT6 Inflammatory Disease Programmes
Gilead Sciences, LEO Pharma, STAT6, inflammatory diseases, partnership, oral formulations, dermatology
2024 FDA Drug Approvals: Small Companies Make Significant Impact
FDA drug approvals 2024, small biotech companies, pharmaceutical industry, new drug approvals, regulatory updates.
Merck & Co. Enters Oral GLP-1 Market with $2 Billion Hansoh Pharma Deal
Merck & Co., Hansoh Pharma, GLP-1 receptor agonist, oral obesity treatment, pharmaceutical collaboration, biotech partnership
EU Regulator to Investigate Potential Link Between Ozempic and Rare Eye Condition NAION
Ozempic, NAION, European Medicines Agency, Novo Nordisk, semaglutide, eye disorder, diabetes drug, investigation
Congress Eyes Major PBM Reforms in Year-End Spending Bill
Pharmacy Benefit Managers (PBMs), PBM reforms, healthcare costs, year-end spending bill, Congress, bipartisan legislation, transparency, drug prices.
EU Regulator Determines Mounjaro Effective for Sleep Apnea, No Separate Approval Required
Mounjaro, sleep apnea, EU regulator, European Medicines Agency (EMA), tirzepatide, weight loss, obesity
Editas Medicine Undergoes Major Restructuring, Laying Off 65% of Staff Including CMO Amid Failed Search for RENI-CEL Partner
Editas Medicine, layoffs, gene editing, biotech, RENI-CEL, sickle cell disease, thalassaemia, CMO, workforce reduction, restructuring.
Editas Medicine Undergoes Major Restructuring, Cutting 65% of Staff and Halting Sickle Cell Therapy Development
Editas Medicine, layoffs, restructuring, sickle cell therapy, CRISPR gene editing, biotech industry
2024 Biotech IPOs: Insights and Trends
Biotech IPOs, 2024 IPO trends, biopharma sector, initial public offerings, venture capital investment, healthcare innovation.